Valuation: Acrux Limited

Market Cap 5.9M 4.11M 3.67M 3.42M 3.11M 5.85M 396M 41.27M 16.06M 202M 15.43M 15.09M 649M P/E 2025
-0.95x
P/E 2026 -8.4x
Enterprise Value 6.71M 4.68M 4.17M 3.89M 3.54M 6.66M 450M 46.96M 18.27M 230M 17.55M 17.18M 739M EV / Sales 2025
2.07x
EV / Sales 2026 1.08x
Free-Float
95.6%
Yield 2025 *
-
Yield 2026 -

Last Transcript: Acrux Limited

1 week+5.26%
Current month+11.11%
1 month-9.09%
3 months-16.67%
6 months-9.09%
Current year-33.33%
1 week 0.01
Extreme 0.009
0.01
1 month 0.01
Extreme 0.009
0.01
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.13
10 years 0.01
Extreme 0.009
0.38
Manager TitleAgeSince
Chief Executive Officer - 31/05/2025
Director of Finance/CFO - 20/06/2021
Chief Tech/Sci/R&D Officer - 23/08/2026
Director TitleAgeSince
Chairman 74 31/12/2005
Director/Board Member - 30/09/2013
Director/Board Member 70 31/05/2016
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+5.26%-33.33%-75.61% 4.1M
+0.02%-3.52%+36.11%+111.11% 1,019B
-1.21%-6.99%+34.08%+60.96% 617B
+1.12%-0.20%+13.62%+80.24% 464B
-3.30%-6.15%+56.45%+34.69% 356B
+0.93%-1.83%+21.65%+41.43% 333B
+0.12%-4.05%+10.70%+33.53% 267B
-0.89%-5.83%-7.00%+7.91% 244B
-0.01%-3.62%+35.28%+52.02% 218B
-0.08%-4.98%+28.34%+93.61% 179B
Average +0.19%-2.26%+19.59%+43.99% 369.72B
Weighted average by Cap. +0.44%-3.63%+28.50%+68.49%

Financials

2025 2026
Net sales 4.49M 3.13M 2.79M 2.6M 2.37M 4.46M 301M 31.41M 12.22M 154M 11.74M 11.49M 494M 6.58M 4.59M 4.09M 3.81M 3.47M 6.53M 442M 46.06M 17.92M 225M 17.22M 16.85M 725M
Net income -5.94M -4.14M -3.7M -3.44M -3.13M -5.9M -399M -41.61M -16.19M -204M -15.55M -15.22M -655M -604K -421K -376K -350K -318K -600K -40.54M -4.23M -1.64M -20.69M -1.58M -1.55M -66.51M
Net Debt 2.77M 1.93M 1.72M 1.61M 1.46M 2.75M 186M 19.4M 7.55M 94.96M 7.25M 7.1M 305M 813K 567K 505K 471K 429K 807K 54.57M 5.69M 2.21M 27.85M 2.13M 2.08M 89.52M
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
05/10/26 A$0.0100 0.00% 5,000
05/10/26 A$0.0100 0.00% 1,401,470
02/10/26 A$0.0100 0.00% 1,392,258
01/10/26 A$0.0100 +11.11% 10,907
30/09/26 A$0.009000 -5.26% 1,083,094

Annual profits - Rate of surprise